Denosumab Demonstrates Superior Bone Mineral Density Gains Compared to Zoledronic Acid in Primary Osteoporosis: A 36-Month Retrospective Analysis — the raw data of this study

Study Title
Denosumab Demonstrates Superior Bone Mineral Density Gains Compared to Zoledronic Acid in Primary Osteoporosis: A 36-Month Retrospective Analysis
Description for Figshare
This study presents a head‑to‑head comparison of denosumab and zoledronic acid for the treatment of primary osteoporosis in a Chinese population. A single‑center retrospective design was used, including 413 patients treated over 36 months (denosumab, n=198; zoledronic acid, n=215). Outcomes assessed were bone mineral density (BMD) at the lumbar spine, femoral neck, and total hip; bone turnover markers (β‑CTX, P1NP); pain (Visual Analog Scale); functional impairment (Oswestry Disability Index); adverse events; and new fractures.
Both treatments significantly improved BMD, bone turnover markers, and clinical symptoms. Denosumab was associated with significantly greater gains in BMD at all measured sites, more pronounced suppression of bone resorption, superior pain relief, and a lower overall incidence of adverse reactions compared with zoledronic acid. New fracture rates were low in both groups and did not differ significantly.
The results provide real‑world evidence supporting denosumab as a favorable option in primary osteoporosis, particularly for patients seeking maximal BMD improvement, those with significant bone pain, or individuals intolerant to bisphosphonates. The dataset includes complete baseline and 36‑month follow‑up information for BMD, biochemical markers, patient‑reported outcomes, and safety events.